Skip to main content
PMC home page
Frontiers in Molecular Neuroscience logoLink to Frontiers in Molecular Neuroscience
. 2021 Jul 9;14:660104. doi: 10.3389/fnmol.2021.660104

Age-Related Transcriptional Deregulation of Genes Coding Synaptic Proteins in Alzheimer's Disease Murine Model: Potential Neuroprotective Effect of Fingolimod

Henryk Jęśko 1,†, Iga Wieczorek 2,†, Przemysław Leonard Wencel 2, Magdalena Gąssowska-Dobrowolska 1, Walter J Lukiw 3, Robert Piotr Strosznajder 2,*
PMCID: PMC8299068  PMID: 34305524

Abstract

Alzheimer's disease (AD) induces time-dependent changes in sphingolipid metabolism, which may affect transcription regulation and neuronal phenotype. We, therefore, analyzed the influence of age, amyloid β precursor protein (AβPP), and the clinically approved, bioavailable sphingosine-1-phosphate receptor modulator fingolimod (FTY720) on the expression of synaptic proteins. RNA was isolated, reverse-transcribed, and subjected to real-time PCR. Expression of mutant (V717I) AβPP led to few changes at 3 months of age but reduced multiple mRNA coding for synaptic proteins in a 12-month-old mouse brain. Complexin 1 (Cplx1), SNAP25 (Snap25), syntaxin 1A (Stx1a), neurexin 1 (Nrxn1), neurofilament light (Nefl), and synaptotagmin 1 (Syt1) in the hippocampus, and VAMP1 (Vamp1) and neurexin 1 (Nrxn1) in the cortex were all significantly reduced in 12-month-old mice. Post mortem AD samples from the human hippocampus and cortex displayed lower expression of VAMP, synapsin, neurofilament light (NF-L) and synaptophysin. The potentially neuroprotective FTY720 reversed most AβPP-induced changes in gene expression (Cplx1, Stx1a, Snap25, and Nrxn1) in the 12-month-old hippocampus, which is thought to be most sensitive to early neurotoxic insults, but it only restored Vamp1 in the cortex and had no influence in 3-month-old brains. Further study may reveal the potential usefulness of FTY720 in the modulation of deregulated neuronal phenotype in AD brains.

Keywords: aging, Alzheimer's disease, amyloid β, FTY720/fingolimod, neurodegeneration, sphingolipids, sphingosine-1-phosphate, synaptic proteins

Introduction

Aging creates a vulnerable background for the development of incurable neurodegenerative disorders, such as Alzheimer's disease (AD), which is characterized by the presence of extracellular senile plaques of amyloid β (Aβ) and neurofibrillary tangles of hyperphosphorylated tau protein. AD is the most common neurodegenerative disorder in the elderly. Its most frequent late-onset, usually sporadic form, follows a long period of stealthy, relatively symptom-free development. Major neuronal populations are already lost when first easily recognizable behavioral outcomes appear, which dramatically hampers both therapy and research on its etiology. Although AD is relatively less frequently caused by inherited genetic mutations, this form of disease raises hopes for a better understanding of AD mechanisms. Aggregation of Aβ peptides is one of the hallmarks of all AD forms, and overexpression of the Aβ precursor protein (AβPP) is frequently used to generate animal models of the disease. In pathological conditions, the normally dominating AβPP cleavage by α- and γ-secretase is partially replaced by amyloidogenic proteolysis by β- and γ-secretase. AβPP mutations may be responsible for the shift in AβPP processing and for the increased Aβ tendency to aggregate. Increasing the local concentration of Aβ, along with its ongoing aggregation, seems to be an important stimulus changing its activity from the supposed physiological stimulation of synaptic plasticity into a neurotoxin (Fagiani et al., 2019).

Although the precise location of Aβ in the chain of events leading to neurodegeneration is still debated, the presence of its excessive amounts in the extracellular space leads to signaling anomalies and free radical stress. Synaptic disturbances are part of early AD, preceding neuronal death by a significant time margin (Fagiani et al., 2019). While large extracellular deposits of Aβ do not correlate precisely with cognitive decline, oligomers and intracellular soluble/aggregated Aβ associate with ultrastructural damage to synapses/distal neurites, and with disease severity (Rajmohan and Reddy, 2017; Marsh and Alifragis, 2018). Oligomers are, therefore, currently viewed as the likely Aβ species capable of driving synaptic pathology (Walsh et al., 2002), which accompanies and most likely predates extensive neurodegeneration (Zamponi and Pigino, 2019). Synaptic alterations are targeted by few treatments currently available for a transient slowing of AD symptoms (Marsh and Alifragis, 2018). The molecular interactions that mediate the detrimental influence of Aβ on synapses most likely involve members and binding partners of the SNARE (soluble N-ethylmaleimide sensitive fusion attachment protein receptor) complex, which ensure structural integrity and regulate synaptic vesicle turnover (Russell et al., 2012; Yang et al., 2015; Koppensteiner et al., 2016; Marsh and Alifragis, 2018). Low concentrations of monomeric Aβ have been suggested to stimulate neurotransmission through stimulation of vesicle fusion (during neurotransmitter secretion) and inhibition of endocytosis (which mediates neurotransmitter removal from the synaptic cleft); pathological, aggregating Aβ, in turn, would predominantly block exocytosis (Fagiani et al., 2019). Aβ has also been found to regulate receptor activities and their feedback endocytosis (Kamenetz et al., 2003; Hsieh et al., 2006). Correspondingly, accumulating evidence suggests that elusive functions of Aβ in a healthy brain could include synaptic regulation (Gulisano et al., 2019). However, while protein–protein interactions of Aβ are gaining attention, comparatively little is known on the possible influence of Aβ/AβPP on the expression of genes, such as those that code synaptic proteins. Aβ interacts with synaptic translation machinery (Ghosh et al., 2020), but there is also a possibility that it could modulate gene expression through modification of the sphingolipid-dependent modulation of transcription factors (Jeśko et al., 2019a,b).

Altered signaling pathways are a major part of the known pathomechanism of synapse and neuron loss. Disturbances in bioactive sphingolipids are observed both in aging and AD (Katsel et al., 2007; Han, 2010; Couttas et al., 2014). Interestingly, these disturbances occur very early in the disease course and seem to diminish in later stages (Han, 2010). Ceramide and its derivative sphingosine typically activate apoptosis, while their respective phosphates (C1P: ceramide-1-phosphate; S1P: sphingosine-1-phosphate) are mostly positive regulators of cellular survival. S1P has a wide array of other functions, modulating acquisition and maintenance of neuronal phenotypes, such as neurotransmission and synaptic plasticity. S1P (and probably C1P) acts either through cell surface receptors, or as second messengers within the cell. The cell membrane receptors for S1P (S1PR1−5) bind to G12/13, Gq, and Gi proteins, and are able to influence transcription factors, such as AP-1, NF-kB, p53, or the splicing regulator SRSF1 (Kaneider et al., 2004; Van Brocklyn and Williams, 2012; Patwardhan et al., 2014; Czubowicz et al., 2019; Jeśko et al., 2019a). Strikingly, Aβ is able to modify the expression of sphingolipid-related genes (Kaneider et al., 2004; Jeśko et al., 2019b, 2020). This may explain the above-mentioned shift from S1P signaling toward ceramide production, which is observed in the brain in the early stages of AD and preceding mild cognitive impairment (MCI) (Katsel et al., 2007; Han, 2010; Couttas et al., 2014). Increased ceramide production also occurs before MCI onset, leading to the idea of pre-MCI, a period when upstream events set the neurodegenerative processes in motion, likely with the significant engagement of sphingolipid-based pathways (Han, 2010). Besides altered survival/death signaling, changes in ceramide levels might also impact AβPP maturation and proteolytic processing, which can lead to increased generation of Aβ, closing the feedback circle of events (Puglielli et al., 2003; Sawamura et al., 2004; Tamboli et al., 2005). S1P has also been known to regulate various secretory pathways (Riganti et al., 2016). Somewhat scattered data also suggest the engagement of sphingolipids in the creation and maintenance of neuronal projections and synapses, which are among the earliest targets of Aβ neurotoxicity (Scheff et al., 2006; Ferreira et al., 2015).

The aim of the study was to characterize the influence of the expression of AβPP carrying familial AD–linked mutation (V717I) on the expression of genes coding selected synaptic proteins in the mouse brain cortex and hippocampus at the age of 3 and 12 months and to examine the impact of treatment with FTY720 (fingolimod, an S1P receptor modulator) on these changes. The results were verified with alterations observed in neocortical and hippocampal samples of human AD cases.

Materials and Methods

Three- and 12-month-old FVB-Tg (Thy1; APP LD2/B6) mice that express AβPP harboring V717I “London” mutation predominantly in the brain and spinal cord neurons were used. The “London” mutation associates with early AD and increases the amounts of Aβ, changing the isoform ratios in favor of the highly neurotoxic Aβ42 (Jeśko et al., 2019b).

Animals

Female FVB-Tg (Thy1; APP LD2/B6) mice overexpressed human AβPP with V717I (“London”) mutation under the control of a fragment of thy 1 promoter that ensured expression specifically in the neurons of the brain and spinal cord. The Animal House of the Mossakowski Medical Research Institute PAS, Warsaw, Poland maintained the mice under specific pathogen-free (SPF) conditions, under controlled temperature and humidity conditions, and a 12-h light/dark cycle. Animals aged 3 or 12 months were treated for 2 weeks daily (15 i.p. injections) with 1 mg/kg b.w. FTY720 (Cayman Chemical, Ann Arbor, Michigan, United States, cat. No 10006292) in 0.9% NaCl, or NaCl only (treatment controls), based on a previous study (Poti et al., 2012; Asle-Rousta et al., 2013; Jeśko et al., 2019b). Mice that did not inherit the transgene were used as transgene controls.

All possible measures were used to reduce the number of used animals and minimize their pain/distress. Initial experiments were performed on a minimal number of animals (typically n = 3–4), and only selected results were confirmed on larger cohorts. The experiments were approved by the IV Local Ethics Committee for Animal Experimentation in Warsaw and the Ministry of Environment (approval no. 67/2015 from July 2, 2016 and no. 139 from August 22, 2016, respectively) and were carried out in accordance with the EC Council Directive of November 24, 1986 (86/609/EEC) following the ARRIVE guidelines, the NIH Guide for the Care and Use of Laboratory Animals, and the “Guidelines for the Use of Animals in Neuroscience Research” by the Society for Neuroscience.

Gene Expression Measurement in Mouse Brain Parts by Real-Time Polymerase Chain Reaction

A day after the last treatment, the animals were decapitated, and cerebral cortices and hippocampi were isolated on ice and flash-frozen in liquid nitrogen. RNA was extracted using TRI-reagent according to the protocol of the manufacturer (Sigma-Aldrich/Merck) and DNA digested with DNase I (Sigma-Aldrich, St. Louis, MO, USA). RNA quantity and quality were measured spectrophotometrically (A260/A280 method). Reverse transcription of 4 μg of total RNA was performed with avian myeloblastosis virus (AMV) enzyme and random sequence primers (High Capacity Reverse Transcription Kit, Applied Biosystems, Foster City, CA, United States). TaqMan Gene Expression Assay kits were used for real-time PCR on Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems/Thermo Fisher Scientific, Foster City, California, USA, cat. No. 4331182). Mm01198853_m1 (Cplx1), Mm01315666_m1 (Nefl), Mm00456201_m1 (Nefm), Mm00660298_m1 (Nrxn1), Mm01276449_m1 (Snap25), Mm00444008_m1 (Stx1a), Mm00449772_m1 (Syn1), Mm00436850_m1 (Syp), Mm00436858_m1 (Syt1), Mm01185107_g1 (Vamp1). Gene expression in tri- to quadruplicate samples was calculated using the ddCt method and normalized against actin beta (Actb - Mm00607939_s1). All measurement plates for each brain part/age combination were calibrated with the same sample. Statistical significance was analyzed with a two-way analysis of variance (ANOVA; GraphPad Software, San Diego, CA, United States); “p” value < 0.05 was deemed statistically significant; experimental results are expressed as means ± SEM (standard error of the mean).

Gene Expression Analysis of Human Post Mortem Brain Samples by Northern Dot Blot Arrays

A guanidine isothiocyanate- and silica gel-based membrane total RNA purification system and miRNA isolation kit (PureLink™ Invitrogen, Carlsbad, CA, United States) were used to isolate total RNA; total RNA concentrations were quantified using RNA 6000 Nano LabChips and a 2100 Bioanalyzer (Caliper Technologies, Mountainview, CA, United States; Agilent Technologies, Palo Alto, CA, United States). Synaptic and cytoskeletal RNA abundances were analyzed and quantified using Northern dot blot arrays as previously described (McLachlan et al., 1988; Lukiw et al., 1990, 2008, 2020). Altered RNA levels of interest were further verified using a quantitative Northern dot blot focusing assay that utilizes a T4 PNK kinase radiolabel system employing [α-32P]-dATP (6,000 Ci/m mol; Invitrogen, Carlsbad, CA, United States) that significantly interrogates the abundance of RNA and miRNA signals (Lukiw et al., 2008, 2020). Northern dot blot signal strengths were quantified using data-acquisition software provided with a GS250 molecular imager (Bio-Rad, Hercules, CA, United States), and graphic presentations (including comparative bar graphs) were performed using Excel algorithms (Microsoft, Seattle, WA, United States) and Adobe Photoshop 6.0 (Adobe Systems, San Jose, CA, United States). Alternately Northern dot blot patterns were analyzed using a cut-and count method. Statistical significance was analyzed using a two-way factorial analysis of variance (p, ANOVA; SAS Institute, Cary, NC, United States). A “p” value < 0.05 was deemed statistically significant; experimental values in the Figures are expressed as means ± standard deviation (SD) of that mean.

The acquisition, handling, experimental, and analytical procedures involving post mortem human brain tissues were carried out in an ethical manner in strict accordance with the ethics review board policies at brain and tissue donor institutions and at the Louisiana State University (LSU) Health Sciences Center. Informed consent from next of kin was obtained at brain and tissue donor institutions for all tissue samples prior to autopsy and donation; coded post mortem brain tissue samples (containing no personal identifying information of the donors) were obtained from the brain and tissue banks listed above. The ethical use of post mortem human brain tissues and their analyses were also carried out in strict accordance with the Institutional Biosafety Committee and the Institutional Review Board Committee (IBC/IRBC) ethical guidelines IBC#18059 and IRBC#6774 at the LSU Health Sciences Center, New Orleans, LA, 70112 United States. Project identification codes: NIA AG18031 and NIA AG038834.

Results

To analyze the effects of Aβ precursor protein (AβPP) expression and administration of the potentially neuroprotective drug fingolimod (FTY720, Gilenya™) on the expression of genes coding for synaptic proteins, we used a mouse model (Jeśko et al., 2019b) expressing AβPP with V717I “London” mutation. The mutation is linked to familial FAD/early onset AD and stimulates the production of Aβ, especially its most toxic 42 amino acid species. Despite obvious limitations shared with other animal models of AD, the mice display a temporal sequence of behavioral alterations characteristic for AD and relatively closely follow disturbances of sphingolipid metabolism we noted in the human brain (Moechars et al., 1999; Van Dorpe et al., 2000; Jeśko et al., 2019b, 2020).

FTY720 is an S1P receptor modulator with characterized bioavailability, currently used because of its capacity to cause internalization of the receptors in immune cells in relapsing-remitting multiple sclerosis, primarily lymphocytes but also in brain astrocytes (Choi et al., 2011). The immune component may also be important for the action of FTY720 in other neurodegeneration-linked diseases (Becker-Krail et al., 2017). FTY720 also exerts its neuroprotective potential through enhanced production of brain-derived neurotrophic factor and modulation of its downstream signaling (Doi et al., 2013; Fukumoto et al., 2014; Becker-Krail et al., 2017). However, its primary recognized biological role is to activate S1PRs, potentially leading to a strong anti-apoptotic signal. Finally, FTY720 has been shown to positively modulate synaptic signaling and to restore long-term synaptic plasticity affected by neurodegenerative insults (Nazari et al., 2016; Darios et al., 2017; Zhang et al., 2020). As Aβ is capable of altering sphingolipid (especially S1P) metabolism, it might result in FTY720-treatable disturbances in survival/death pathways (Jeśko et al., 2019b). However, it might also deregulate the known engagement of sphingolipids in gene regulation, such as those coding for synaptic proteins (Cai et al., 2008).

Results from this study show reduced Vamp1 mRNA in the cerebral cortex of 3-month-old mice expressing V717I AβPP transgene. Administration of FTY720 had no effect (Figure 1). Cplx1, Nrxn1, Syn1, and Snap25 remained unchanged in the 3-month-old AβPP mouse brain cortex. Similarly, Nefl and Nefm were not changed (Supplementary Figure 1).

Figure 1.

Figure 1

Open in a new tab

Levels of mRNA coding for synaptic protein VAMP1 in 3-month-old mouse cortex–effect of AβPP expression and FTY720 administration. Levels of mRNAs measured with real-time PCR in the cerebral cortex of 3-month-old (adult) mice as described in Materials and methods. Results from AβPP-expressing mice were compared with those from control animals that did not inherit the transgene. Effect of FTY720 administration was assessed against vehicle-treated animals of the same group. Vamp1, vesicle-associated membrane protein 1; APP−, animals without V717I AβPP transgene; APP+, mice expressing V717I AβPP transgene. ***p < 0.001 vs. corresponding controls, two-way ANOVA followed by Tukey's post-hoc test (significances marked over the horizontal bar describe the difference between vehicle-treated control animals and vehicle-treated AβPP-expressing mice). n = 6–7, measured in tri- to quadruplicate ± SEM.

The pattern of mRNA changes in the hippocampus of 3-month-old AβPP-expressing mice also included a reduction in Vamp1; the SNARE-interacting partner Syt1 was also significantly reduced. FTY720 had no effect on their levels (Figure 2). Among the SNARE proteins, we did not observe any changes in the expression of Stx1a or Snap25 mRNA. Syn1 showed some tendency toward reduction but did not reach significance (Supplementary Figure 2). Nefl and Nefm remained unchanged (Supplementary Figure 2).

Figure 2.

Figure 2

Open in a new tab

Levels of mRNAs coding for synaptic proteins VAMP1 and SYT1 in the 3-month-old mouse hippocampus: effect of AβPP and FTY720. Levels of mRNAs measured in the hippocampus of 3-month-old (adult) mice as described in Materials and methods. mRNA levels in AβPP-expressing mice were compared with control animals that did not inherit the transgene. Effect of FTY720 administration was assessed against vehicle-treated animals in each group. Vamp1, vesicle-associated membrane protein 1; Syt1, synaptotagmin 1; APP−, animals without V717I AβPP transgene; APP+, mice expressing V717I AβPP transgene. *p < 0.05 vs. corresponding controls, two-way ANOVA followed by Tukey's post-hoc test (horizontal bars: effect of AβPP). n = 3–4, measured in triplicate ± SEM.

Twelve-month-old mice expressing V717I AβPP demonstrated reduced expression of numerous genes coding for synaptic proteins. Vamp1 mRNA was again significantly reduced in AβPP-expressing brain cortex compared with controls that did not inherit the transgene (Figure 3). FTY720 treatment returned its expression to near control levels. Nrxn1 mRNA was also reduced by AβPP expression, but FTY720 had no effect on it. No changes were observed in 12-month-old brain cortex in the mRNA levels of Stx1a, Cplx1, Syt1, Syp, Syn1, or Snap25 in response to AβPP (Figure 3). However, FTY720 treatment increased Cplx1, Snap25, Stx1a, and Syt1 in the transgenic animals. Nefl and Nefm remained unchanged (Figure 3).

Figure 3.

Figure 3

Open in a new tab

Levels of mRNAs coding for synaptic proteins in 12-month-old cortex: effect of AβPP and FTY720. Levels of mRNAs measured with real-time PCR in the cerebral cortex of 12-month-old (old adult) mice as described in Materials and methods. mRNA levels in AβPP-expressing mice were compared with control animals that did not inherit the transgene. Effect of FTY720 administration was assessed against vehicle-treated animals in each group. Snap25, synaptosomal-associated protein, 25kDa; Stx1a, syntaxin 1A; Vamp1, vesicle-associated membrane protein 1; Nrxn1, neurexin 1; Cplx1, complexin 1; Syt1, synaptotagmin 1; Syp, synaptophysin; Syn1, synapsin 1; Nefl, neurofilament light; Nefm, neurofilament medium; APP−, animals without V717I AβPP transgene; APP+, mice expressing V717I AβPP transgene. *p < 0.05 vs. corresponding controls, two-way ANOVA followed by Tukey's post-hoc test (horizontal bars: effect of AβPP; significances marked over FTY720 values: effect of FTY720 treatment within each animal group). n = 3–6, measured in triplicate (n = 6–9 for Cplx1, Snap25, Syn1, and Nefl) ± SEM.

Also, at 12 months, hippocampal mRNA levels were significantly lower in AβPP-expressing animals compared with non-transgenic controls: Snap25, Stx1a, Nrxn1, and Cplx1. FTY720 reversed these changes. Syt1 mRNA was also reduced in AβPP-expressing hippocampus, but FTY720 did not change it significantly. Vamp1 and Syp remained unaltered by AβPP expression, but both responded positively to FTY720. We also observed that Nefl mRNA dropped significantly in AβPP animals, while Syn1 and Nefm remained unchanged (Figure 4).

Figure 4.

Figure 4

Open in a new tab

Levels of mRNAs coding for synaptic proteins in 12-month-old hippocampus: effect of AβPP and FTY720. Levels of mRNAs measured with real-time PCR in the hippocampus of 12-month-old (old adult) mice as described in Materials and methods. mRNA levels in AβPP-expressing mice were compared with control animals that did not inherit the transgene. Effect of FTY720 administration was assessed against vehicle-treated animals in each group. Snap25, synaptosomal-associated protein, 25kDa; Stx1a, syntaxin 1A; Vamp1, vesicle-associated membrane protein 1; Nrxn1, neurexin 1; Cplx1, complexin 1; Syt1, synaptotagmin 1; Syp, synaptophysin; Syn1, synapsin 1; Nefl, neurofilament light; Nefm, neurofilament medium; APP−, animals without V717I AβPP transgene; APP+, mice expressing V717I AβPP transgene. *p < 0.05; **p < 0.01; ***p < 0.001 vs. corresponding controls, two-way ANOVA followed by Tukey's post-hoc test (horizontal bars: effect of AβPP; significances marked over FTY720 values: effect of FTY720 treatment within each animal group). n = 3–6, measured in triplicate (n = 7–14 for Cplx1, Syp, Syn1, Vamp1, and Nefl) ± SEM.

Analysis of data from nine human AD samples (Figure 5) indicated a reduced expression of VAMP, synaptophysin, synapsin, and NF-L in comparison to 15 healthy controls. The changes were significant in both neocortical and hippocampal materials. Similar results were obtained using Northern dot blot array methodologies.

Figure 5.

Figure 5

Open in a new tab

Selective down-regulation of the expression of genes coding for synaptic proteins in AD. (A) Neocortical and hippocampal down-regulation of VAMP, synaptophysin, synapsin, and the neuron-specific neurofilament light (NF-L) chain messenger RNA in Alzheimer's disease vs. age-, gender-, and post mortem interval-matched controls using the β-actin cytoskeletal as an internal “housekeeping gene” and expression control. Importantly, the low abundance of the neuron-specific NF-L mRNA cannot be adequately accounted for by a non-specific effect of brain damage, neuron cell loss, or loss of neurons with neurofibrillary degeneration (McLachlan et al., 1988; Lukiw et al., 2018). The AD group (N = 3) had a mean age of 76.1 ± 11.4 years and a mean post mortem (PMI; death to brain-freezing period) of ~3.4 h and the control group (N = 3) had a mean age of 75.5 ± 12.7 years and a mean PMI of ~3.5 h; all brain samples were from female donors; there was no significant difference in the mean age, gender, PMI, or yield of total RNA between the AD and control groups. Total RNA was extracted and probed for α-tubulin, VAMP, synaptophysin, synapsin, the neurofilament light and medium neurofilaments, and quantified based on unchanging β-actin control levels in the same sample using methods explained in detail in previously published study from our laboratories (McLachlan et al., 1988; Lukiw et al., 2008, 2018); deficits in synapse-relevant gene expression were consistently found to be NF-L < synapsin < synaptophysin < VAMP; these observations are also consistent with synaptic signaling deficits in AD brain compared to three unchanging biomarkers: β-actin, α-tubulin, and the NF-M chain protein; *p < 0.05; **p < 0.01 (ANOVA). (B) Down-regulation of mRNAs coding for vesicle-associated membrane protein (VAMP), synaptophysin (SYP), synapsin, and NF-L in Alzheimer's disease vs. age- gender- and post-mortem interval-matched controls using the β-actin cytoskeletal as a “housekeeping gene” and expression control using DNA array analysis (McLachlan et al., 1988; Lukiw et al., 2008, 2018); the numbers 1–3 along the top represent results from N = 3 control and N = 3 Alzheimer cases; again, all were age-matched from female donors; there was no significant difference in the mean age, PMI, or yield of total RNA between the AD and control groups. (C) Selective deficits for synapse-relevant gene expression were also observed in AD temporal lobe neocortex compared with age- and gender-matched controls using Northern dot blot analysis. Deficits in gene expression for synaptic components in control (N = 9) vs. AD (N = 9) female superior temporal lobe (Brodmann A22) neocortices using quantitative Northern dot blots for signal quantitation; the PMI for all tissues was ~4 h or less; a 288-gene matrix was generated using a Biomek 2000 robot (Beckman-Coulter Life Sciences, Indianapolis, IN, United States) at a Northern dot blot density of about 30 genes/cm2; in (C), each vertical column represents the Northern dot blot signature of one control or one AD brain, and each horizontal row represents the hybridization signals from one particular synaptic-relevant probe; signal intensity of each dot in the dot blot is proportional to the abundance of that specific mRNA in the sample; note significant deficits in signal strength (signal intensity of the dot blot) for NF-L, synapsin, synaptophysin, and vesicle-associated membrane protein (VAMP) and negligible changes between control and AD for α-tubulin, NF-M, the amyloid precursor protein (APP), tau, the 43 kDa growth associated protein GAP43 (neuromodulin), the cytoskeletal protein β-actin, glial fibrillary acidic protein (GFAP), and the large ribosomal subunit 28S RNA. In these DNA array studies, the control group (N = 9) had a mean age of 77.5 ± 13.5 years, and the AD group (N = 9) had a mean age of 78.5 ± 11.8 years; all brain samples were from female donors; again, there was no significant difference in the mean age, gender, PMI, or yield of total RNA between the AD and control groups. Experimental values in all of the Figures are expressed as mean ± standard deviation of that mean. This figure represents updated and additional new information for NF-L gene expression data adapted from earlier studies on specific cytoskeletal gene abundance in control and AD neocortex (McLachlan et al., 1988; Lukiw et al., 1990).

Discussion

Our previous analysis (Jeśko et al., 2019b, 2020) has shown that the reaction of mouse brain to the expression of AβPP (V717I) transgene is highly different at various ages. The presence of AβPP in adult (3-month-old) animals was associated with elevated ceramide turnover (higher expression of both ceramide-synthesizing and -degrading enzymes of the salvage pathway of sphingolipid metabolism), but 12-month-old transgenic mice only displayed a reduction in the expression of ceramide-utilizing enzymes in the sphingomyelinase pathway. The effects of such changes may include the well-documented intensification of pro-apoptotic signaling. Literature points to an early rise in the predominantly pro-apoptotic ceramide and disturbed production of S1P, which, in most situations, supports cell survival, in human AD brains. Disturbances in ceramide/sphingolipid metabolism appear very early (leading to the proposal of pre-MCI phase that would precede the mild cognitive impairment), correlate with the severity of neurodegeneration, and, strikingly, diminish in later disease stages (Katsel et al., 2007; Han, 2010; Couttas et al., 2014).

Altered sphingolipid signaling may also heavily affect neuronal phenotype, as sphingolipids regulate glutamate secretion, the expression of glutamate receptor subunits, and probably the shape and structure of neurites and synapses (Riganti et al., 2016; Joshi et al., 2017). Synapse loss is one of the early features of AD and correlates with the ongoing cognitive deterioration (Scheff et al., 2006; Ferreira et al., 2015). Deregulation and eventual degeneration of synaptic connections is largely dependent on Aβ levels (Forner et al., 2019; Sharda et al., 2020). Disruption of lipid rafts, which are sphingolipid-enriched microdomains in the neuronal membrane, is a known trigger of synapse loss (Hering et al., 2003). Inhibition of ceramide synthesis, or exogenous addition of sphingosine, causes axon growth blockade and axon retraction in cultured neurons (Campenot et al., 1991; Harel and Futerman, 1993). Inhibition of ceramide synthase also disturbs dendrite formation in cultured neurons (Furuya et al., 1995). Manipulation of ceramide metabolism alters numerous neuronal signaling systems, such as NMDA, AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), and acetylcholine receptors, reviewed in Olsen and Færgeman (2017). Metabolism of AβPP and production of Aβ are also highly dependent on the rafts (Czubowicz et al., 2019). The synaptic targets that bind Aβ and may mediate synapse loss could include some neurexin and neuroligin isoforms, glutamate, adrenergic, and nicotinic receptors, calcium channels, or GM1 ganglioside (Ferreira et al., 2015; Brito-Moreira et al., 2017). However, Aβ might also deregulate synaptic homeostasis through alteration of the role of sphingolipids in gene regulation (Jeśko et al., 2019b, 2020), which is mostly realized through cell surface S1P receptors (S1PR1-5), G proteins, and the PI3K (phosphoinositide 3-kinase)–Akt pathway (Jeśko et al., 2019a). PI3K/Akt–dependent transcription factors include AP-1 and NF-κB. Interestingly, promoter of the human SNAP25 synaptic protein gene contains sites binding sphingolipid-regulated transcription factors AP-1 and Sp1 (specificity protein 1) (Cai et al., 2008; Zou et al., 2011; Hsu et al., 2015). The potential of Aβ to cause synaptic disruption prompted us to analyze the levels of mRNA coding for selected synaptic proteins in the AβPP (V717I) transgenic mouse model.

The results showed decreased expression of several crucial genes coding SNARE proteins and their interacting partners in (V717I) AβPP transgenic mice. At the age of 3 months, the changes were limited to reduced Vamp1 mRNA (both in the cerebral cortex and hippocampus) and Syt1 (only in the hippocampus), (Figures 1, 2). These changes might signify an already ongoing disruption of synaptic structure. Administration of the potentially neuroprotective S1P receptor modulator FTY720 has not changed the abnormal expression of Syt1 or Vamp1 in 3-month-old AβPP transgenic mice.

In contrast to the young adults, we observed numerous gene expression changes in 12-month-old AβPP-expressing animals. Vamp1 and Nrxn1 mRNAs were reduced in the cerebral cortex, while other measured mRNAs (such as Cplx1, Snap25, Syp, and Stx1a) remained at the same level as in non-AβPP controls (Figure 3). Nrxn1 mRNA was reduced in both investigated 12-month-old brain parts. FTY720 reversed the decrease in Vamp1 but not Nrxn1 mRNAs; and the compound also had a positive influence on Cplx1, Snap25, Stx1a, and Syt1 in the 12-month-old animals (Figure 3).

Opposite to the cerebral cortex, the 12-month-old hippocampus displayed a nearly uniform reduction in Cplx1, Snap25, Stx1a, Nrxn1, Syt1, and Nefl but not Vamp1 mRNA, which seems to reflect unique sensitivity of the brain part to the gradually accumulating effects of Aβ/AβPP. The reduction in Snap25, Syt1 as well as Vamp1 hippocampal gene expression is consistent with previously observed changes in the human AD hippocampus (Berchtold et al., 2013). Importantly, reduction in Cplx1, Snap25, Stx1a, and Nrxn1 could be reversed by FTY720, which also increased the levels of Vamp1 and Syp.

We next evaluated the expression of selected synaptic protein-coding genes in samples from high quality human brain tissues with post mortem intervals (PMIs) of 2.4 h or less (Figure 5). Interestingly, the patterns of AD-linked changes in the human hippocampus and neocortex were very similar to each other, but the set of genes affected showed a noticeable similarity to the mouse model. We observed reduced expression of VAMP, SYP, SYN, and NF-L (NEFL) mRNAs, in both brain regions.

VAMP1, STX1A, and SNAP25 belong to the SNARE complex critically implicated in vesicular secretion of neurotransmitters, in the membrane insertion of receptor proteins, and also in synaptic plasticity, axon guidance, or nerve regeneration (Ulloa et al., 2018; Madrigal et al., 2019). Several lines of evidence suggest the possible engagement of SNARE proteins in AD, although data are rather limited: polymorphisms in VAMP1 and STX genes associate with AD; VAMP1 can modulate Aβ secretion; while VAMP2 levels are disturbed in AD (Sevlever et al., 2015; Vallortigara et al., 2016; Costa et al., 2019). The SNARE trimer binds a multitude of other proteins, such as regulators (synaptotagmin–SYT, complexin–CPLX), and also α-synuclein (Almandoz-Gil et al., 2018; Alford et al., 2019; Hawk et al., 2019; Karmakar et al., 2019). SYT1 is engaged in Ca2+ sensing and coupling of calcium signal to neurotransmitter release; genetic SYT ablation can lead to disturbed synaptic vesicle exocytosis, such as uncontrolled (spontaneous) release (Volynski and Krishnakumar, 2018). SYT1, -2, -7, and -9 bind AβPP; SYT1 probably supports AβPP processing by β-secretase (Gautam et al., 2015; Barthet et al., 2018). SYT1 also interacts with presenilin 1, and experimental disruption of their interaction increases the proportion of the highly neurotoxic Aβ42 (Zoltowska et al., 2017). Moreover, SYT1 levels and SYT1–presenilin 1 binding are disturbed in the brain of humans with AD (Zoltowska et al., 2017).

Neurexins (NRXN) are single-pass transmembrane proteins located predominantly in the presynaptic part; they bind post-synaptic neuroligins (NLGN), neurexophilins, and dystroglycan systems ensuring structural properties of neuronal connections. Neurexins also influence differentiation and synaptic vesicle production. Their sensitivity to calcium allows for direct regulation of NLGN–NRXN binding by neuron activity (Sindi et al., 2014). Neurexin mutations may predispose to AD (Sindi et al., 2014). Aβ impairs the expression of NRXN1β and can bind NRXN2A (Brito-Moreira et al., 2017; Naito et al., 2017). Interactions of NRXN with Aβ/secretases can lead to, e.g., accumulation of NRXN fragments in the extracellular space, membranes, and pre-synaptic cytoplasm, and finally to altered efficiency of synaptic transmission [discussed in Sindi et al. (2014)] but also to structural disruption and loss of synapses (Brito-Moreira et al., 2017; Naito et al., 2017). The reduction of Nrxn1 and Vamp1 expression we observed might be a part of advancing synaptic deterioration. However, the known association of AD risk with VAMP1 polymorphisms that cause increased transcription, and the positive influence of VAMP1 on Aβ secretion (Sevlever et al., 2015) suggest an ambiguous role for the protein. We cannot rule out a neuroprotective outcome of Vamp1 reduction, and some potentially homeostatic reactions might occur even relatively late in the disease progression.

Synaptophysin (SYP) is a cholesterol-binding membrane protein that transiently interacts with VAMP in an activity-dependent manner (Hübner et al., 2002; Khvotchev and Südhof, 2004). The significance of SYP for synaptic function/maintenance is unclear because of the lack of gross gene ablation-induced phenotypes. However, reduced synaptophysin has long been noted in aging and in a disease-specific, spatially-restricted manner in early stages of AD and some other neurodegeneration types (Masliah et al., 1989; Lippa, 2004; Martin et al., 2014). Reduced SYP also correlates with AD severity (Sze et al., 1997; Heffernan et al., 1998). Loss of SYP staining is observed in neurons in the vicinity of Aβ oligomer deposits (Ishibashi et al., 2006); interaction of SYP with internalized Aβ and Aβ-induced preferential SYP nitration have been suggested to mediate synaptic disturbances observed in AD (Tran et al., 2003; Russell et al., 2012). Reduction of Syp expression was also observed in neurons containing neurofibrillary tangles (Callahan et al., 1999).

Synapsins (SYN) are highly abundant, neuron-specific pre-synaptic vesicle proteins engaged in synaptogenesis, regulation of vesicle storage, fusion, and resulting neurotransmitter release (Song and Augustine, 2015). SYN disturbances are noted in multiple neurodegenerative/psychiatric disorders, including AD (Qin et al., 2004; Song and Augustine, 2015). Specifically, loss of SYN1 has been previously observed in some layers of CA1 and dentate gyrus of patients with AD hippocampus (Qin et al., 2004). Moreover, a reduction in Syn1 mRNA levels was observed in the CA3 layer of the hippocampus of rats with sporadic AD (Bolognin et al., 2012). Similar results were also reported by Berchtold et al. who observed structure-specific downregulation of SYN1 mRNA levels in the hippocampus of patients with AD. Interestingly, cortical SYN1 mRNA reduction was observed in the aged control group (69–99 vs. 20–50 years) (Berchtold et al., 2013).

The results also confirm reduced expression of NEFL (NF-L), which encodes the 68 kDa neurofilament protein. NF-L is a neuron-specific intermediate filament being a critical scaffolding component of neurite extensions, the primary regulator of axon diameter, overall neuronal cytoarchitecture, neuron shape and morphology, and an integral component of synaptic complexes (Palermo et al., 2020). Down-regulated NF-L within degenerating neocortical neurons, such as those seen in AD, correlates well with the neuronal atrophy and deterioration widely observed in progressive neurological degeneration (Berchtold et al., 2013). Diminished brain levels of NF-L have been reported by several independent laboratories in AD and in transgenic murine models for AD (TgAD) irrespective of reduced neuron count (Lukiw et al., 1990, 2018; Loeffler et al., 2020). NF-L may be a diagnostic biomarker of brain atrophy and disease progression in multiple nervous system disorders (Gaetani et al., 2019; Antonell et al., 2020).

The difference between human and rodent samples could stem from several sources. First, although the (V717I) AβPP-expressing mice relatively successfully recreate a spectrum of AD pathology aspects, they still share the obvious limitations of all rodent AD models. Second, human post mortem samples are collected at much more advanced stages of widespread, massive neurodegeneration, in contrast to the mild degenerative changes observed in 12-month-old (V717I) AβPP mouse brains. Moreover, some differences in the spatial distribution of sensitivity to Aβ neurotoxicity between the human and mouse brains might also modify the outcome.

The results, therefore, show that the impact of Aβ/AβPP on critical synaptic components is highly dependent on age/disease stage and is brain part specific, with the highest number of changes occurring in the 12-month-old hippocampi (all changes that were observed in 12-month-old transgenic mice were presented in Figure 6). FTY720 is capable of reversing many of Aβ/AβPP-induced changes in the expression of synaptic proteins, suggesting its value as a research tool and possibly a repurposed drug. Although the mouse model obviously examines the disease at a much earlier stage (and at a much younger age) than observed in human tissues, we noted several striking similarities in the obtained results. Therefore, we can suggest that the sensitivity of several key synaptic components to FTY720 administration may also be present in the human nervous system. Synaptic deterioration is a relatively early stage of degeneration in AD, but its biochemical manifestations appear to persist to the end stage.

Figure 6.

Figure 6

Open in a new tab

Schematic representation of changes in genes coding synaptic proteins and their possible consequences observed in 12-month (12 M) FVB/AβPP (V717I) mice cortex and hippocampus. The effect of fingolimod (FTY720, marked by green dashed square) on genes that expression was altered in AD mice brain was bolded and marked with circles (ellipses). Snap25, synaptosomal-associated protein, 25kDa; Stx1a, syntaxin 1A; Vamp1, vesicle-associated membrane protein 1; Nrxn1, neurexin 1; Cplx1, complexin 1; Syt1, synaptotagmin 1; Syp, synaptophysin; Nefl, neurofilament light.

The pleiotropic activities of FTY720 require further attention to the potential mechanism of its restorative action. One plausible explanation is the ability of S1P receptors to modulate transcription factors, such as AP-1 or NF-kappa B, therefore relatively directly and specifically affecting the transcription of multiple genes (including feedback regulation of sphingolipid metabolic enzymes) (Jeśko et al., 2019a,b; Jeśko et al., 2020). S1P and its receptors also have a complex influence on PI3 kinase/Akt and their signaling target mTOR, potentially influencing gene transcription and translation through ribosomal protein S6 kinases, eukaryotic translation initiation factor 4E-binding proteins, and FOXO transcription factors (Jeśko et al., 2019a). Both sphingosine kinase 2 and its product S1P can modulate histone deacetylases (Jeśko et al., 2019a). More general influences of FTY720 on AβPP metabolism and inflammation may add further layers of complexity. FTY720, acting as a ligand, can cause regulatory internalization of S1PR protein, effectively inhibiting S1PR signaling in lymphocytes and blocking their egress from secondary lymphoid organs. This effect is exploited in the therapy of relapsing remitting multiple sclerosis (Sica et al., 2019). FTY720 also reduces the numbers of activated microglia and astrocytes in the brain of rodent AD models, normalizing cytokines, synaptic morphology, plasticity, and learning performance (Hemmati et al., 2013; Aytan et al., 2016). Anti-inflammatory effects of FTY720 have also been shown in other diseases, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Huntington's disease (HD), neuronal ceroid lipofuscinoses, and neonatal hyperoxia (Bascuñana et al., 2020). Although feedback S1PR internalization upon ligation has been considered the main mechanism of the anti-inflammatory action of FTY720, the atypical dose-response characteristics suggest that agonistic action on S1PRs may also be important in this case, possibly involving two different mechanisms depending on compound concentration (Aytan et al., 2016). Moreover, FTY720 might be most effective in concentrations that reduce microglia and astrocyte activation but do not affect peripheral lymphocytes (Carreras et al., 2019).

Much study has also been conducted on the effects of FTY720 on amyloid beta accumulation. FTY720 can decrease the accumulation of soluble and plaque Aβ, probably through an increased phagocytic capacity of astrocytes and reduced microgliosis (McManus et al., 2017; Kartalou et al., 2020). Takasugi observed that reduction of Aβ load by FTY720 and change in the proportions between Aβ40 and Aβ42 may occur in the presence of Gi inhibitor suramin, therefore likely independently of the currently known S1PR-dependent signaling pathways, possibly through direct binding of FTY720 to γ-secretase or AβPP (FTY720 decreased the γ-secretase mediated cleavage of AβPP) (Takasugi et al., 2013).

The gradual evolution of the Aβ/AβPP-associated changes in synaptic composition we observed in aging AβPP transgenic mice occurs along with the known Aβ-induced disruption of synaptic protein-protein interactions (Marsh and Alifragis, 2018). This phenomenon suggests the necessity of wide, in-depth characterization of the feasibility of Aβ-induced synaptic changes as a potential druggable target in AD. Irrespective of the mentioned cautions, the observed effects of FTY720 administration on synaptic protein expression suggest restorative potential, in accordance with the currently prevailing view on the action of FTY720 in AD and other neurodegenerative disorders.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Ethics Statement

The studies involving human participants were reviewed and approved by the ethical use of postmortem human brain tissues and their analyses were also carried out in strict accordance with the Institutional Biosafety Committee and the Institutional Review Board Committee (IBC/IRBC) ethical guidelines IBC#18059 and IRBC#6774 at the LSU Health Sciences Center, New Orleans LA 70112 USA. Project identification codes: NIA AG18031 and NIA AG038834. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements. The animal study was reviewed and approved by the IV Local Ethics Committee for Animal Experimentation in Warsaw and the Ministry of Environment (approval no. 67/2015 from 2nd July 2016 and no. 139 from 22nd August 2016, respectively) and were carried out in accordance with the EC Council Directive of November 24, 1986 (86/609/EEC) following the ARRIVE guidelines, the NIH Guide for the Care and Use of Laboratory Animals, and the Guidelines for the Use of Animals in Neuroscience Research by the Society for Neuroscience.

Author Contributions

RS and WL: conceptualization and formal analysis. HJ, IW, PW, RS, and WL: methodology and investigation. RS: validation, resources, supervision, project administration, and funding acquisition. RS and PW: data curation. HJ: writing – original draft preparation. HJ and RS: writing – review and editing. IW and PW: visualization. All authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

We would like to sincerely thank the many neuropathologists, physicians, and researchers of Canada, Europe, the Russian Federation, and the USA for their cooperation and provision of high-quality, short postmortem interval (PMI) human CNS or brain tissues for scientific analysis and study.

Glossary

Abbreviations

Aβ

amyloid β

AβPP

Aβ precursor protein

ACTB

actin beta

AD

Alzheimer's disease

CNS

central nervous system

CPLX1

complexin 1

FTY720

fingolimod/Gilenya™

GAP43

Growth-associated protein 43/neuromodulin

GFAP

glial fibrillary acidic protein

NF-L

neurofilament light chain

NF-M

neurofilament medium chain

NRXN1

neurexin 1

S1P

sphingosine-1-phosphate

S1PR

S1P receptor

SNAP25

synaptosomal-associated protein 25kDa

SNARE

soluble N-ethylmaleimide sensitive fusion attachment protein receptor

Sp1

specificity protein 1

STX1A

syntaxin 1A

SYN1

synapsin 1

SYT1

synaptotagmin 1

SYP

synaptophysin

t-SNARE

target membrane SNARE protein

VAMP1

vesicle-associated membrane protein 1

v-SNARE

vesicular side SNARE protein.

The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Aging, the National Center for Research Resources, or the National Institutes of Health.

Footnotes

Funding. The study was supported by the National Science Centre (PL) (Grant no. NCN 2014/15/B/NZ3/01049) and the statutory budget of MMRI PAS theme no. 7 (Figures 1–4). Research on synaptic and neurofilament gene expression involving synaptogenesis and neuro-inflammation in AD and in other human neurological- and plant-viroid-based diseases (Figure 5) was supported through an unrestricted grant to the LSU Eye Center from Research to Prevent Blindness (RPB); the Louisiana Biotechnology Research Network (LBRN) and NIH grants NEI EY006311, NIA AG18031, and NIA AG038834 (WL). AD and age-matched control human hippocampus and temporal lobe and/or neocortical tissues were obtained from brain and tissue repositories including the LSU Health Sciences Center archives, the University of Oregon Health Sciences Center (OHSC), NIH collaborators and researchers, and by the Institute for Memory Impairments and Neurological Disorders and the University of California at Irvine Alzheimer's Disease Research Center (UCI-ADRC). Funding for the UCI-ADRC was provided by NIH/NIA Grant P50 AG16573. Funding bodies had no role in the design, execution, interpretation, or writing of the study.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnmol.2021.660104/full#supplementary-material

Supplementary Figure 1

Levels of mRNA coding for synaptic proteins in 3-month-old mouse cortex: effect of AβPP expression and FTY720 administration. Levels of mRNAs measured with real-time PCR in the cerebral cortex of 3-month-old (adult) mice as described in Materials and methods. Results from AβPP-expressing mice were compared with those from control animals that did not inherit the transgene. Effect of FTY720 administration was assessed against vehicle-treated animals of the same group. Snap25, synaptosomal-associated protein, 25kDa; Stx1a, syntaxin 1A; Nrxn1, neurexin 1; Cplx1, complexin 1; Syt, synaptotagmin 1; Syp, synaptophysin; Syn1, synapsin 1; Nefl, neurofilament light; Nefm, neurofilament medium; APP−, animals without V717I AβPP transgene; APP+, mice expressing V717I AβPP transgene. n = 3–4 (for Nrxn1, Cplx1, Syt1, and Syp), n = 6–8 (for Snap25, Stx1a, Syn1, Nefl, and Nefm) measured in triplicate.

Click here for additional data file. (944.5KB, JPEG)
Supplementary Figure 2

Levels of mRNA coding for synaptic proteins in 3-month-old mouse hippocampus: effect of AβPP expression and FTY720 administration. Levels of mRNAs measured with real-time PCR in the hippocampus of 3-month-old (adult) mice as described in Materials and methods. Results from AβPP-expressing mice were compared with those from control animals that did not inherit the transgene. Effect of FTY720 administration was assessed against vehicle-treated animals of the same group. Snap25, synaptosomal-associated protein, 25kDa; Stx1a, syntaxin 1A; Nrxn1, neurexin 1; Cplx1, complexin 1; Syp, synaptophysin; Syn1, synapsin 1; Nefl, neurofilament light; Nefm, neurofilament medium; APP−, animals without V717I AβPP transgene; APP+, mice expressing V717I AβPP transgene. n = 3–4 measured in triplicate (for Snap25, Nrxn1, Syp, Syn1, Nefl, and Nefm) (n = 6–8 for Stx1a and Cplx1).

Click here for additional data file. (895.2KB, JPEG)

References

  1. Alford S., Hamm H., Rodriguez S., Zurawski Z. (2019). Gβγ SNARE interactions and their behavioral effects. Neurochem. Res. 44, 636–649. 10.1007/s11064-018-2531-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Almandoz-Gil L., Persson E., Lindström V., Ingelsson M., Erlandsson A., Bergström J. (2018). In situ proximity ligation assay reveals co-localization of alpha-synuclein and SNARE proteins in murine primary neurons. Front. Neurol. 9:180. 10.3389/fneur.2018.00180 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Antonell A., Tort-Merino A., Ríos J., Balasa M., Borrego-Écija S., Auge J. M., et al. (2020). Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. Alzheimers Dement. 16, 262–272. 10.1016/j.jalz.2019.09.001 [DOI] [PubMed] [Google Scholar]
  4. Asle-Rousta M., Kolahdooz Z., Oryan S., Ahmadiani A., Dargahi L. (2013). FTY720 (fingolimod) attenuates beta-amyloid peptide (Aβ42)-induced impairment of spatial learning and memory in rats. J. Mol. Neurosci. 50, 524–532. 10.1007/s12031-013-9979-6 [DOI] [PubMed] [Google Scholar]
  5. Aytan N., Choi J. K., Carreras I., Brinkmann V., Kowall N. W., Jenkins B. G., et al. (2016). Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer's disease. Sci. Rep. 6:24939. 10.1038/srep24939 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Barthet G., Jordà-Siquier T., Rumi-Masante J., Bernadou F., Müller U., Mulle C. (2018). Presenilin-mediated cleavage of APP regulates synaptotagmin-7 and presynaptic plasticity. Nat. Commun. 9:4780. 10.1038/s41467-018-06813-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bascuñana P., Möhle L., Brackhan M., Pahnke J. (2020). Fingolimod as a treatment in neurologic disorders beyond multiple sclerosis. Drugs R D 20, 197–207. 10.1007/s40268-020-00316-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Becker-Krail D., Farrand A. Q., Boger H. A., Lavin A. (2017). Effects of fingolimod administration in a genetic model of cognitive deficits. J. Neurosci. Res. 95, 1174–1181. 10.1002/jnr.23799 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Berchtold N. C., Coleman P. D., Cribbs D. H., Rogers J., Gillen D. L., Cotman C. W. (2013). Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer's disease. Neurobiol. Aging 34, 1653–1661. 10.1016/j.neurobiolaging.2012.11.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Bolognin S., Blanchard J., Wang X., Basurto-Islas G., Tung Y. C., Kohlbrenner E., et al. (2012). An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide. Acta Neuropathol. 123, 133–151. 10.1007/s00401-011-0908-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Brito-Moreira J., Lourenco M. V., Oliveira M. M., Ribeiro F. C., Ledo J. H., Diniz L. P., et al. (2017). Interaction of amyloid-β (Aβ) oligomers with neurexin 2α and neuroligin 1 mediates synapse damage and memory loss in mice. J. Biol. Chem. 292, 7327–7337. 10.1074/jbc.M116.761189 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cai F., Chen B., Zhou W., Zis O., Liu S., Holt R. A., et al. (2008). SP1 regulates a human SNAP-25 gene expression. J. Neurochem. 105, 512–523. 10.1111/j.1471-4159.2007.05167.x [DOI] [PubMed] [Google Scholar]
  13. Callahan L. M., Vaules W. A., Coleman P. D. (1999). Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer disease neurons containing neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 58, 275–287. 10.1097/00005072-199903000-00007 [DOI] [PubMed] [Google Scholar]
  14. Campenot R. B., Walji A. H., Draker D. D. (1991). Effects of sphingosine, staurosporine, and phorbol ester on neurites of rat sympathetic neurons growing in compartmented cultures. J. Neurosci. 11, 1126–1139. 10.1523/JNEUROSCI.11-04-01126.1991 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Carreras I., Aytan N., Choi J.-K., Tognoni C. M., Kowall N. W., Jenkins B. G., et al. (2019). Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer's disease. Sci. Rep. 9, 10972–10972. 10.1038/s41598-019-47287-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Choi J. W., Gardell S. E., Herr D. R., Rivera R., Lee C. W., Noguchi K., et al. (2011). FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc. Natl. Acad. Sci. U. S. A. 108, 751–756. 10.1073/pnas.1014154108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Costa A. S., Guerini F. R., Arosio B., Galimberti D., Zanzottera M., Bianchi A., et al. (2019). SNARE complex polymorphisms associate with alterations of visual selective attention in Alzheimer's disease. J. Alzheimers Dis. 69, 179–188. 10.3233/JAD-190147 [DOI] [PubMed] [Google Scholar]
  18. Couttas T. A., Kain N., Daniels B., Lim X. Y., Shepherd C., Kril J., et al. (2014). Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis. Acta Neuropathol. Commun. 2:9. 10.1186/2051-5960-2-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Czubowicz K., Jeśko H., Wencel P., Lukiw W. J., Strosznajder R. P. (2019). The Role of ceramide and sphingosine-1-phosphate in Alzheimer's disease and other neurodegenerative disorders. Mol. Neurobiol. 56, 5436–5455. 10.1007/s12035-018-1448-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Darios F. D., Jorgacevski J., Flašker A., Zorec R., García-Martinez V., Villanueva J., et al. (2017). Sphingomimetic multiple sclerosis drug FTY720 activates vesicular synaptobrevin and augments neuroendocrine secretion. Sci. Rep. 7:5958. 10.1038/s41598-017-05948-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Doi Y., Takeuchi H., Horiuchi H., Hanyu T., Kawanokuchi J., Jin S., et al. (2013). Fingolimod phosphate attenuates oligomeric amyloid β-induced neurotoxicity via increased brain-derived neurotrophic factor expression in neurons. PLoS ONE 8:e61988. 10.1371/journal.pone.0061988 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Fagiani F., Lanni C., Racchi M., Pascale A., Govoni S. (2019). Amyloid-β and synaptic vesicle dynamics: a cacophonic orchestra. J. Alzheimers Dis. 72, 1–14. 10.3233/JAD-190771 [DOI] [PubMed] [Google Scholar]
  23. Ferreira S. T., Lourenco M. V., Oliveira M. M., De Felice F. G. (2015). Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease. Front. Cell Neurosci. 9:191. 10.3389/fncel.2015.00191 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Forner S., Martini A. C., Prieto G. A., Dang C. T., Rodriguez-Ortiz C. J., Reyes-Ruiz J. M., et al. (2019). Intra- and extracellular β-amyloid overexpression via adeno-associated virus-mediated gene transfer impairs memory and synaptic plasticity in the hippocampus. Sci. Rep. 9:15936. 10.1038/s41598-019-52324-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Fukumoto K., Mizoguchi H., Takeuchi H., Horiuchi H., Kawanokuchi J., Jin S., et al. (2014). Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid β-induced memory impairment. Behav. Brain Res. 268, 88–93. 10.1016/j.bbr.2014.03.046 [DOI] [PubMed] [Google Scholar]
  26. Furuya S., Ono K., Hirabayashi Y. (1995). Sphingolipid biosynthesis is necessary for dendrite growth and survival of cerebellar Purkinje cells in culture. J. Neurochem. 65, 1551–1561. 10.1046/j.1471-4159.1995.65041551.x [DOI] [PubMed] [Google Scholar]
  27. Gaetani L., Blennow K., Calabresi P., Di Filippo M., Parnetti L., Zetterberg H. (2019). Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. Neurosurg. Psychiatry 90, 870–881. 10.1136/jnnp-2018-320106 [DOI] [PubMed] [Google Scholar]
  28. Gautam V., D'Avanzo C., Berezovska O., Tanzi R. E., Kovacs D. M. (2015). Synaptotagmins interact with APP and promote Aβ generation. Mol. Neurodegener. 10:31. 10.1186/s13024-015-0028-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Ghosh A., Mizuno K., Tiwari S. S., Proitsi P., Gomez Perez-Nievas B., Glennon E., et al. (2020). Alzheimer's disease-related dysregulation of mRNA translation causes key pathological features with ageing. Transl. Psychiatry 10:192. 10.1038/s41398-020-00882-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Gulisano W., Melone M., Ripoli C., Tropea M. R., Li Puma D. D., Giunta S., et al. (2019). Neuromodulatory action of picomolar extracellular Aβ42 oligomers on presynaptic and postsynaptic mechanisms underlying synaptic function and memory. J. Neurosci. 39, 5986–6000. 10.1523/JNEUROSCI.0163-19.2019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Han X. (2010). Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease. Biochim. Biophys. Acta 1801, 774–783. 10.1016/j.bbalip.2010.01.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Harel R., Futerman A. H. (1993). Inhibition of sphingolipid synthesis affects axonal outgrowth in cultured hippocampal neurons. J. Biol. Chem. 268, 14476–14481. 10.1016/S0021-9258(19)85263-8 [DOI] [PubMed] [Google Scholar]
  33. Hawk B. J. D., Khounlo R., Shin Y. K. (2019). Alpha-synuclein continues to enhance SNARE-dependent vesicle docking at exorbitant concentrations. Front. Neurosci. 13:216. 10.3389/fnins.2019.00216 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Heffernan J. M., Eastwood S. L., Nagy Z., Sanders M. W., McDonald B., Harrison P. J. (1998). Temporal cortex synaptophysin mRNA is reduced in Alzheimer's disease and is negatively correlated with the severity of dementia. Exp. Neurol. 150, 235–239. 10.1006/exnr.1997.6772 [DOI] [PubMed] [Google Scholar]
  35. Hemmati F., Dargahi L., Nasoohi S., Omidbakhsh R., Mohamed Z., Chik Z., et al. (2013). Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: comparison with memantine. Behav. Brain Res. 252, 415–421. 10.1016/j.bbr.2013.06.016 [DOI] [PubMed] [Google Scholar]
  36. Hering H., Lin C. C., Sheng M. (2003). Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J. Neurosci. 23, 3262–3271. 10.1523/JNEUROSCI.23-08-03262.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Hsieh H., Boehm J., Sato C., Iwatsubo T., Tomita T., Sisodia S., et al. (2006). AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52, 831–843. 10.1016/j.neuron.2006.10.035 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Hsu C. K., Lee I. T., Lin C. C., Hsiao L. D., Yang C. M. (2015). Sphingosine-1-phosphate mediates COX-2 expression and PGE2 /IL-6 secretion via c-Src-dependent AP-1 activation. J. Cell Physiol. 230, 702–715. 10.1002/jcp.24795 [DOI] [PubMed] [Google Scholar]
  39. Hübner K., Windoffer R., Hutter H., Leube R. E. (2002). Tetraspan vesicle membrane proteins: synthesis, subcellular localization, and functional properties. Int. Rev. Cytol. 214, 103–159. 10.1016/S0074-7696(02)14004-6 [DOI] [PubMed] [Google Scholar]
  40. Ishibashi K., Tomiyama T., Nishitsuji K., Hara M., Mori H. (2006). Absence of synaptophysin near cortical neurons containing oligomer Abeta in Alzheimer's disease brain. J. Neurosci. Res. 84, 632–636. 10.1002/jnr.20952 [DOI] [PubMed] [Google Scholar]
  41. Jeśko H., Stepień A., Lukiw W. J., Strosznajder R. P. (2019a). The cross-talk between sphingolipids and insulin-like growth factor signaling: significance for aging and neurodegeneration. Mol. Neurobiol. 56, 3501–3521. 10.1007/s12035-018-1286-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Jeśko H., Wencel P. L., Lukiw W. J., Strosznajder R. P. (2019b). Modulatory effects of fingolimod (FTY720) on the expression of sphingolipid metabolism-related genes in an animal model of Alzheimer's disease. Mol. Neurobiol. 56, 174–185. 10.1007/s12035-018-1040-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Jeśko H., Wencel P. L., Wójtowicz S., Strosznajder J., Lukiw W. J., Strosznajder R. P. (2020). Fingolimod affects transcription of genes encoding enzymes of ceramide metabolism in animal model of Alzheimer's disease. Mol. Neurobiol. 57, 2799–2811. 10.1007/s12035-020-01908-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Joshi P., Gabrielli M., Ponzoni L., Pelucchi S., Stravalaci M., Beeg M., et al. (2017). Fingolimod limits acute Aβ neurotoxicity and promotes synaptic versus extrasynaptic NMDA receptor functionality in hippocampal neurons. Sci. Rep. 7:41734. 10.1038/srep41734 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., et al. (2003). APP processing and synaptic function. Neuron 37, 925–937. 10.1016/S0896-6273(03)00124-7 [DOI] [PubMed] [Google Scholar]
  46. Kaneider N. C., Lindner J., Feistritzer C., Sturn D. H., Mosheimer B. A., Djanani A. M., et al. (2004). The immune modulator FTY720 targets sphingosine-kinase-dependent migration of human monocytes in response to amyloid beta-protein and its precursor. FASEB J. 18, 1309–1311. 10.1096/fj.03-1050fje [DOI] [PubMed] [Google Scholar]
  47. Karmakar S., Sharma L. G., Roy A., Patel A., Pandey L. M. (2019). Neuronal SNARE complex: a protein folding system with intricate protein-protein interactions, and its common neuropathological hallmark, SNAP25. Neurochem. Int. 122, 196–207. 10.1016/j.neuint.2018.12.001 [DOI] [PubMed] [Google Scholar]
  48. Kartalou G.-I., Salgueiro-Pereira A. R., Endres T., Lesnikova A., Casarotto P., Pousinha P., et al. (2020). Anti-inflammatory treatment with FTY720 starting after onset of symptoms reverses synaptic deficits in an AD mouse model. Int. J. Mol. Sci. 21:8957. 10.3390/ijms21238957 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Katsel P., Li C., Haroutunian V. (2007). Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? Neurochem. Res. 32, 845–856. 10.1007/s11064-007-9297-x [DOI] [PubMed] [Google Scholar]
  50. Khvotchev M. V., Südhof T. C. (2004). Stimulus-dependent dynamic homo- and heteromultimerization of synaptobrevin/VAMP and synaptophysin. Biochemistry 43, 15037–15043. 10.1021/bi048290+ [DOI] [PubMed] [Google Scholar]
  51. Koppensteiner P., Trinchese F., Fà M., Puzzo D., Gulisano W., Yan S., et al. (2016). Time-dependent reversal of synaptic plasticity induced by physiological concentrations of oligomeric Aβ42: an early index of Alzheimer's disease. Sci. Rep. 6:32553. 10.1038/srep32553 [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Lippa C. F. (2004). Synaptophysin immunoreactivity in Pick's disease: comparison with Alzheimer's disease and dementia with Lewy bodies. Am. J. Alzheimers Dis. Other Demen. 19, 341–344. 10.1177/153331750401900606 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Loeffler T., Schilcher I., Flunkert S., Hutter-Paier B. (2020). Neurofilament-light chain as biomarker of neurodegenerative and rare diseases with high translational value. Front. Neurosci. 14:579. 10.3389/fnins.2020.00579 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Lukiw W. J., Cong L., Jaber V., Zhao Y. (2018). Microbiome-derived lipopolysaccharide (LPS) selectively inhibits neurofilament light chain (NF-L) gene expression in human neuronal-glial (HNG) cells in primary culture. Front. Neurosci. 12:896. 10.3389/fnins.2018.00896 [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Lukiw W. J., Pogue A., Hill J. M. (2020). SARS-CoV-2 infectivity and neurological targets in the brain. Cell Mol. Neurobiol.1–8. 10.1007/s10571-020-00947-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Lukiw W. J., Wong L., McLachlan D. R. (1990). Cytoskeletal messenger RNA stability in human neocortex: studies in normal aging and in Alzheimer's disease. Int. J. Neurosci. 55, 81–88. 10.3109/00207459008985953 [DOI] [PubMed] [Google Scholar]
  57. Lukiw W. J., Zhao Y., Cui J. G. (2008). An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J. Biol. Chem. 283, 31315–31322. 10.1074/jbc.M805371200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Madrigal M. P., Portalés A., SanJuan M. P., Jurado S. (2019). Postsynaptic SNARE proteins: role in synaptic transmission and plasticity. Neuroscience 420, 12–21. 10.1016/j.neuroscience.2018.11.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Marsh J., Alifragis P. (2018). Synaptic dysfunction in Alzheimer's disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention. Neural Regen. Res. 13, 616–623. 10.4103/1673-5374.230276 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Martin S. B., Dowling A. L., Lianekhammy J., Lott I. T., Doran E., Murphy M. P., et al. (2014). Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer's disease. J. Alzheimers Dis. 42, 767–775. 10.3233/JAD-140795 [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Masliah E., Terry R. D., DeTeresa R. M., Hansen L. A. (1989). Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci. Lett. 103, 234–239. 10.1016/0304-3940(89)90582-X [DOI] [PubMed] [Google Scholar]
  62. McLachlan D. R., Lukiw W. J., Wong L., Bergeron C., Bech-Hansen N. T. (1988). Selective messenger RNA reduction in Alzheimer's disease. Brain Res. 427, 255–261. 10.1016/0169-328X(88)90048-4 [DOI] [PubMed] [Google Scholar]
  63. McManus R. M., Finucane O. M., Wilk M. M., Mills K. H. G., Lynch M. A. (2017). FTY720 Attenuates infection-induced enhancement of Aβ accumulation in APP/PS1 mice by modulating astrocytic activation. J. Neuroimmune Pharmacol. 12, 670–681. 10.1007/s11481-017-9753-6 [DOI] [PubMed] [Google Scholar]
  64. Moechars D., Dewachter I., Lorent K., Reversé D., Baekelandt V., Naidu A., et al. (1999). Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274, 6483–6492. 10.1074/jbc.274.10.6483 [DOI] [PubMed] [Google Scholar]
  65. Naito Y., Tanabe Y., Lee A. K., Hamel E., Takahashi H. (2017). Amyloid-β oligomers interact with neurexin and diminish neurexin-mediated excitatory presynaptic organization. Sci. Rep. 7:42548. 10.1038/srep42548 [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Nazari M., Keshavarz S., Rafati A., Namavar M. R., Haghani M. (2016). Fingolimod (FTY720) improves hippocampal synaptic plasticity and memory deficit in rats following focal cerebral ischemia. Brain Res. Bull. 124, 95–102. 10.1016/j.brainresbull.2016.04.004 [DOI] [PubMed] [Google Scholar]
  67. Olsen A. S. B., Færgeman N. J. (2017). Sphingolipids: membrane microdomains in brain development, function and neurological diseases. Open Biol. 7:170069. 10.1098/rsob.170069 [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Palermo G., Mazzucchi S., Della Vecchia A., Siciliano G., Bonuccelli U., Azuar C., et al. (2020). Different clinical contexts of use of blood neurofilament light chain protein in the spectrum of neurodegenerative diseases. Mol. Neurobiol. 57, 4667–4691. 10.1007/s12035-020-02035-9 [DOI] [PubMed] [Google Scholar]
  69. Patwardhan G. A., Hosain S. B., Liu D. X., Khiste S. K., Zhao Y., Bielawski J., et al. (2014). Ceramide modulates pre-mRNA splicing to restore the expression of wild-type tumor suppressor p53 in deletion-mutant cancer cells. Biochim. Biophys. Acta 1841, 1571–1580. 10.1016/j.bbalip.2014.08.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Poti F., Costa S., Bergonzini V., Galletti M., Pignatti E., Weber C., et al. (2012). Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R?/?) mice. Vascul Pharmacol. 57, 56–64. 10.1016/j.vph.2012.03.003 [DOI] [PubMed] [Google Scholar]
  71. Puglielli L., Ellis B. C., Saunders A. J., Kovacs D. M. (2003). Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J. Biol. Chem. 278, 19777–19783. 10.1074/jbc.M300466200 [DOI] [PubMed] [Google Scholar]
  72. Qin S., Hu X. Y., Xu H., Zhou J. N. (2004). Regional alteration of synapsin I in the hippocampal formation of Alzheimer's disease patients. Acta Neuropathol. 107, 209–215. 10.1007/s00401-003-0800-4 [DOI] [PubMed] [Google Scholar]
  73. Rajmohan R., Reddy P. H. (2017). Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer's disease neurons. J. Alzheimers Dis. 57, 975–999. 10.3233/JAD-160612 [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Riganti L., Antonucci F., Gabrielli M., Prada I., Giussani P., Viani P., et al. (2016). Sphingosine-1-phosphate (S1P) impacts presynaptic functions by regulating synapsin I localization in the presynaptic compartment. J. Neurosci. 36, 4624–4634. 10.1523/JNEUROSCI.3588-15.2016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Russell C. L., Semerdjieva S., Empson R. M., Austen B. M., Beesley P. W., Alifragis P. (2012). Amyloid-β acts as a regulator of neurotransmitter release disrupting the interaction between synaptophysin and VAMP2. PLoS ONE 7:e43201. 10.1371/journal.pone.0043201 [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Sawamura N., Ko M., Yu W., Zou K., Hanada K., Suzuki T., et al. (2004). Modulation of amyloid precursor protein cleavage by cellular sphingolipids. J. Biol. Chem. 279, 11984–11991. 10.1074/jbc.M309832200 [DOI] [PubMed] [Google Scholar]
  77. Scheff S. W., Price D. A., Schmitt F. A., Mufson E. J. (2006). Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging 27, 1372–1384. 10.1016/j.neurobiolaging.2005.09.012 [DOI] [PubMed] [Google Scholar]
  78. Sevlever D., Zou F., Ma L., Carrasquillo S., Crump M. G., Culley O. J., et al. (2015). Genetically-controlled vesicle-associated membrane protein 1 expression may contribute to Alzheimer's pathophysiology and susceptibility. Mol. Neurodegener. 10:18. 10.1186/s13024-015-0047-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Sharda N., Pengo T., Wang Z., Kandimalla K. K. (2020). Amyloid-β peptides disrupt interactions between VAMP-2 and SNAP-25 in neuronal cells as determined by FRET/FLIM. J. Alzheimers Dis. 77, 423–435. 10.3233/JAD-200065 [DOI] [PubMed] [Google Scholar]
  80. Sica F., Centonze D., Buttari F. (2019). Fingolimod immune effects beyond its sequestration ability. Neurol. Ther. 8, 231–240. 10.1007/s40120-019-00162-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Sindi I. A., Tannenberg R. K., Dodd P. R. (2014). Role for the neurexin-neuroligin complex in Alzheimer's disease. Neurobiol. Aging 35, 746–756. 10.1016/j.neurobiolaging.2013.09.032 [DOI] [PubMed] [Google Scholar]
  82. Song S. H., Augustine G. J. (2015). Synapsin isoforms and synaptic vesicle trafficking. Mol. Cells 38, 936–940. 10.14348/molcells.2015.0233 [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Sze C. I., Troncoso J. C., Kawas C., Mouton P., Price D. L., Martin L. J. (1997). Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J. Neuropathol. Exp. Neurol. 56, 933–944. 10.1097/00005072-199708000-00011 [DOI] [PubMed] [Google Scholar]
  84. Takasugi N., Sasaki T., Ebinuma I., Osawa S., Isshiki H., Takeo K., et al. (2013). FTY720/fingolimod, a sphingosine analogue, reduces amyloid-β production in neurons. PLoS ONE 8:e64050. 10.1371/journal.pone.0064050 [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Tamboli I. Y., Prager K., Barth E., Heneka M., Sandhoff K., Walter J. (2005). Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. J. Biol. Chem. 280, 28110–28117. 10.1074/jbc.M414525200 [DOI] [PubMed] [Google Scholar]
  86. Tran M. H., Yamada K., Nakajima A., Mizuno M., He J., Kamei H., et al. (2003). Tyrosine nitration of a synaptic protein synaptophysin contributes to amyloid beta-peptide-induced cholinergic dysfunction. Mol. Psychiatry 8, 407–412. 10.1038/sj.mp.4001240 [DOI] [PubMed] [Google Scholar]
  87. Ulloa F., Cotrufo T., Ricolo D., Soriano E., Araújo S. J. (2018). SNARE complex in axonal guidance and neuroregeneration. Neural Regen. Res. 13, 386–392. 10.4103/1673-5374.228710 [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Vallortigara J., Whitfield D., Quelch W., Alghamdi A., Howlett D., Hortobágyi T., et al. (2016). Decreased levels of VAMP2 and monomeric alpha-synuclein correlate with duration of dementia. J. Alzheimers Dis. 50, 101–110. 10.3233/JAD-150707 [DOI] [PubMed] [Google Scholar]
  89. Van Brocklyn J. R., Williams J. B. (2012). The control of the balance between ceramide and sphingosine-1-phosphate by sphingosine kinase: oxidative stress and the seesaw of cell survival and death. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 163, 26–36. 10.1016/j.cbpb.2012.05.006 [DOI] [PubMed] [Google Scholar]
  90. Van Dorpe J., Smeijers L., Dewachter I., Nuyens D., Spittaels K., Van Den Haute C., et al. (2000). Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. Am. J. Pathol. 157, 1283–1298. 10.1016/S0002-9440(10)64644-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Volynski K. E., Krishnakumar S. S. (2018). Synergistic control of neurotransmitter release by different members of the synaptotagmin family. Curr. Opin. Neurobiol. 51, 154–162. 10.1016/j.conb.2018.05.006 [DOI] [PubMed] [Google Scholar]
  92. Walsh D. M., Klyubin I., Fadeeva J. V., Cullen W. K., Anwyl R., Wolfe M. S., et al. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535–539. 10.1038/416535a [DOI] [PubMed] [Google Scholar]
  93. Yang Y., Kim J., Kim H. Y., Ryoo N., Lee S., Kim Y., et al. (2015). Amyloid-β oligomers may impair SNARE-mediated exocytosis by direct binding to syntaxin 1a. Cell Rep. 12, 1244–1251. 10.1016/j.celrep.2015.07.044 [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Zamponi E., Pigino G. F. (2019). Protein misfolding, signaling abnormalities and altered fast axonal transport: implications for Alzheimer and prion diseases. Front. Cell Neurosci. 13:350. 10.3389/fncel.2019.00350 [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Zhang J., Xiao B., Li C. X., Wang Y. (2020). Fingolimod (FTY720) improves postoperative cognitive dysfunction in mice subjected to D-galactose-induced aging. Neural Regen. Res. 15, 1308–1315. 10.4103/1673-5374.272617 [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Zoltowska K. M., Maesako M., Lushnikova I., Takeda S., Keller L. J., Skibo G., et al. (2017). Dynamic presenilin 1 and synaptotagmin 1 interaction modulates exocytosis and amyloid β production. Mol. Neurodegener. 12:15. 10.1186/s13024-017-0159-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Zou X., Gao Y., Ruvolo V. R., Gardner T. L., Ruvolo P. P., Brown R. E. (2011). Human glycolipid transfer protein gene (GLTP) expression is regulated by Sp1 and Sp3: involvement of the bioactive sphingolipid ceramide. J. Biol. Chem. 286, 1301–1311. 10.1074/jbc.M110.127837 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Figure 1

Levels of mRNA coding for synaptic proteins in 3-month-old mouse cortex: effect of AβPP expression and FTY720 administration. Levels of mRNAs measured with real-time PCR in the cerebral cortex of 3-month-old (adult) mice as described in Materials and methods. Results from AβPP-expressing mice were compared with those from control animals that did not inherit the transgene. Effect of FTY720 administration was assessed against vehicle-treated animals of the same group. Snap25, synaptosomal-associated protein, 25kDa; Stx1a, syntaxin 1A; Nrxn1, neurexin 1; Cplx1, complexin 1; Syt, synaptotagmin 1; Syp, synaptophysin; Syn1, synapsin 1; Nefl, neurofilament light; Nefm, neurofilament medium; APP−, animals without V717I AβPP transgene; APP+, mice expressing V717I AβPP transgene. n = 3–4 (for Nrxn1, Cplx1, Syt1, and Syp), n = 6–8 (for Snap25, Stx1a, Syn1, Nefl, and Nefm) measured in triplicate.

Click here for additional data file. (944.5KB, JPEG)
Supplementary Figure 2

Levels of mRNA coding for synaptic proteins in 3-month-old mouse hippocampus: effect of AβPP expression and FTY720 administration. Levels of mRNAs measured with real-time PCR in the hippocampus of 3-month-old (adult) mice as described in Materials and methods. Results from AβPP-expressing mice were compared with those from control animals that did not inherit the transgene. Effect of FTY720 administration was assessed against vehicle-treated animals of the same group. Snap25, synaptosomal-associated protein, 25kDa; Stx1a, syntaxin 1A; Nrxn1, neurexin 1; Cplx1, complexin 1; Syp, synaptophysin; Syn1, synapsin 1; Nefl, neurofilament light; Nefm, neurofilament medium; APP−, animals without V717I AβPP transgene; APP+, mice expressing V717I AβPP transgene. n = 3–4 measured in triplicate (for Snap25, Nrxn1, Syp, Syn1, Nefl, and Nefm) (n = 6–8 for Stx1a and Cplx1).

Click here for additional data file. (895.2KB, JPEG)

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Articles from Frontiers in Molecular Neuroscience are provided here courtesy of Frontiers Media SA

RESOURCES